ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00705159
Recruitment Status : Completed
First Posted : June 25, 2008
Results First Posted : August 11, 2011
Last Update Posted : March 24, 2015
Sponsor:
Information provided by (Responsible Party):
Bausch & Lomb Incorporated

Brief Summary:
The objective of this study is to evaluate the safety and effectiveness of Zylet in comparison with Lotemax, Tobramycin and the vehicle of Zylet for the treatment of blepharoconjunctivitis in pediatric subjects.

Condition or disease Intervention/treatment Phase
Conjunctivitis Drug: loteprednol etabonate and tobramycin Drug: loteprednol etabonate Drug: Tobramycin Drug: Vehicle of Zylet Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 137 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis
Study Start Date : June 2008
Actual Primary Completion Date : March 2010
Actual Study Completion Date : May 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pinkeye

Arm Intervention/treatment
Experimental: Loteprednol etabonate and tobramycin
Drug: Zylet (loteprednol etabonate and tobramycin)
Drug: loteprednol etabonate and tobramycin
Topical ocular administration of loteprednol etabonate and tobramycin 4 times per day (QID) for 14 days.
Other Name: Zylet

Active Comparator: Loteprednol etabonate
Drug: Lotemax (loteprednol etabonate)
Drug: loteprednol etabonate
Topical ocular administration of Lotemax (loteprednol etabonate) QID for 14 days.
Other Name: Lotemax

Active Comparator: Tobramycin
Drug: Tobramycin
Drug: Tobramycin
Topical ocular administration of Tobramycin QID for 14 days.

Placebo Comparator: Vehicle
Vehicle of Zylet
Drug: Vehicle of Zylet
Topical ocular administration of the vehicle of Zylet QID for 14 days.




Primary Outcome Measures :
  1. Change From Baseline in the Total Blepharoconjunctivitis Grade. [ Time Frame: Baseline to 15 days ]
    Change from baseline to visit 4 in the total blepharoconjunctivitis grade. Graded on a scale of 0-4, 0 (none), 1 (minimal/trace), 2 (mild), 3 (moderate), and 4 (severe). Grade range from 0-32.


Secondary Outcome Measures :
  1. Change From Baseline in Total Blepharoconjunctivitis Graded at Visit 2 [ Time Frame: Baseline to Day 3 ]
    Change from baseline in total blepharoconjunctivitis grade to visit 2(day 3) measured on a scale of 0-4. 0 (none), 1 (minimal/trace), 2 (mild), 3 (moderate), and 4 (severe). Grade range from 0-32.

  2. Change From Baseline in Total Blepharoconjunctivitis Graded at Visit 3 [ Time Frame: Baseline to Day 7 ]
    Change from baseline in total blepharoconjunctivitis grade to visit 3(day 7) measured on a scale of 0-4. 0 (none), 1 (minimal/trace), 2 (mild), 3 (moderate), and 4 (severe). Grade range from 0-32.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 6 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • children 0-6 years of age.
  • clinical diagnosis of blepharoconjunctivitis
  • Parent/guardian must understand, be willing and able to comply with all treatment and follow-up procedures.
  • Parent/guardian must understand, be willing and able to provide informed consent and Health Insurance Portability Accountability Act (HIPAA) authorization.

Exclusion Criteria:

  • Known hypersensitivity to corticosteroids, aminoglycosides, or any component of the study medication.
  • Subjects who have a history of ocular surgery, including laser procedures, within the past 6 months.
  • Subjects who are monocular.
  • Subjects who have a history of any severe/serious ocular pathology or medical condition that could result in the subject's inability to complete the study.
  • Subjects who have participated in an ophthalmic drug or device research study within 30 days prior to entry in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00705159


Locations
United States, Pennsylvania
Pediatric Ophthalmology of Erie
Erie, Pennsylvania, United States, 16501
Sponsors and Collaborators
Bausch & Lomb Incorporated

Responsible Party: Bausch & Lomb Incorporated
ClinicalTrials.gov Identifier: NCT00705159     History of Changes
Other Study ID Numbers: 550
First Posted: June 25, 2008    Key Record Dates
Results First Posted: August 11, 2011
Last Update Posted: March 24, 2015
Last Verified: March 2015

Keywords provided by Bausch & Lomb Incorporated:
Blepharokeratoconjunctivitis

Additional relevant MeSH terms:
Conjunctivitis
Conjunctival Diseases
Eye Diseases
Tobramycin
Loteprednol Etabonate
Anti-Bacterial Agents
Anti-Infective Agents
Anti-Allergic Agents